GLP-1 Weight Loss Injections/Medication

talk to me

GLP-1 Weight Loss Injections/Medication

talk to me

Content

Introduction

In recent years, Semaglutide has gained widespread attention both in clinical settings and across social media. This treatment has been long recognised as an effective treatment for managing type 2 diabetes, but has been FDA-approved as a medical weight loss treatment in 2021.

Many well known individuals, such as Tech Billionaire, Elon Musk, shared their remarkable transformations on the internet. Collectively known as the GLP-1 Receptor Agonist class of medications, common examples include Ozempic (Semaglutide), Wegovy (semaglutide), Saxenda (Liraglutide), and  Rybelsus (Semaglutide).

Common trending weight loss medications in singapore.
GLP-1 Weight Loss Medications containing Semaglutide, such as Wegovy or Ozempic are trending on the internet.
Elon Musk Ozempic weight loss
Elon Musk has been open about using Ozempic, in combination with intermittent fasting, to achieve his body transformation.

Overview of GLP 1 weight loss medications

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone in the body that plays a key role in regulating appetite and blood sugar levels. Generally, when we consume food, GLP-1 is released in the gut, which triggers the brain to reduce hunger, slow down digestion and manage blood glucose levels. 

Weight loss medications, such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), work by mimicking this hormone, aiding in weight loss by:

  • Increasing feelings of fullness
  • Reducing hunger
  • Lowers blood sugar levels by boosting insulin secretion
  • Decreases glucagon secretion
  • Slows gastric emptying
  • Supports extended periods of activity 

GLP-1 medication vs older weight loss medications

Before the rise of GLP-1 medications, weight loss medications often involved drugs that take effect on the central nervous system to reduce hunger or increase energy expenditure. This includes phentermine and diethylpropion. 

FeatureGLP-1 MedicationsOlder Weight Loss Medications
MechanismMimics GLP-1 hormone that naturally occurs in the bodyStimulates the central nervous system

Indications for treatment

Weight loss medications are indicated for patients who are obese and suffer from obesity related complications, despite best efforts at weight loss through lifestyle modification (ie- diet and exercise). Weight loss medications are prescribed to to patients who are:

  • Obese – BMI > 30
  • Overweight – BMI > 27 with comorbidities such as diabetes, cardiovascular diseases, or high blood pressure

That being said, you can still consult your doctor if you’re struggling to lose weight despite your best efforts. A professional consultation could be the key to uncovering any underlying factors and exploring medical-grade solutions to help you overcome this plateau. 

What is medical weight loss?

Medical weight loss generally refers to a holistic weight loss programme where treatment is tailored specifically to your condition, goals, and is closely supervised by a medical professional. This often involves weight loss medication prescribed by your doctor to aid in losing weight in addition to a proper diet and regular exercise. 

  • Professional guidance — Your weight loss journey will be overseen by a healthcare provider, who closely monitors your progress and ensures that your treatment plan is safe and tailored to your needs.
  • Medications — When appropriate, medications such as Saxenda or Wegovy are prescribed to achieve weight reduction
  • Customised plans — As there is no one-size-fits-all approach to weight loss, your treatment plan is highly customised to your body type and condition.
  • Long-term management — The main goal in mind is sustainable weight loss to ensure that you do not regain weight. This means your treatment plan will also include proper habit-building and lifestyle changes. 
Medical weight loss in Singapore
Medical weight loss is a weight loss programme conducted under the supervision of doctors.

What medications are used for medical weight loss? How do they work?

Several weight loss medications approved by the US FDA and Singapore HSA include:

  • OzempicSemaglutide injection used to treat type 2 diabetes. It is also used to treat obesity by improving glycemic control.
  • Wegovy — Similar to ozempic, wegovy contains semaglutide and helps weight management and reduces risks of major cardiovascular events such as heart attacks.
  • Rybelsus — Rybelsus is an oral tablet formulation of semaglutide to treat type 2 diabetes and reduce blood sugar levels. It is meant to be taken once daily.
  • SaxendaLiraglutide injection for obesity management in adults and children aged 12 - 17.

These medications contain semaglutide or liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which binds to GLP-1 receptors and promotes insulin secretion [2, 3]. Semaglutide and liraglutide also reduce release of glucagon, a hormone that increases blood sugar levels, as well as inhibit gluconeogenesis, a process of converting glycogen in the liver to glucose in the blood. Essentially, the medications work by suppressing appetite and increasing satiety.

Liraglutide injection singapore
Saxenda (liraglutide) works by suppressing appetite while increasing satiety, making you feel full quicker

Are there any side effects to medical weight loss medications?

Some side effects of Semaglutide and Liraglutide are [2, 4]:

  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Indigestion
  • Abdominal cramps
  • Fatigue
  • Headaches 

However, these side effects usually only occur in the first few weeks of treatment as your body acclimates to the medication, and are tolerable for most patients. However, if you experience extreme symptoms, such as severe abdominal pain, changes in heart rate or mood changes, it is important to consult your doctor immediately. 

What can I expect from a medical weight loss consultation?

Before giving you a prescription for weight loss medication, you will need a consultation session with your doctor. Everyone’s weight loss journey is different, and this allows your doctor to assess your suitability and gain a better understanding of your medical history, weight loss challenges, and current health condition before coming up with a personalised treatment plan for you. It is also important to inform your doctor if you are taking any other medicines for other conditions as there may be contraindications.

Depending on the type of drug, the dosage may be administered differently.

  • Injections – Injections of semaglutide or liraglutide are given once a week, the dosage depends on the type of medication. The starting dose starts from 0.25mg for semaglutide and 0.6mg for liraglutide, and is increased over time [4].
  • Oral tablets – Oral tablets of Rybelsus (semaglutide) are to be taken on an empty stomach 30 minutes before your first meal. Typically, the starting dose is a single 3mg tablet once daily for 30 days, and it may be increased over time [2].

Medical supervision is necessary throughout the course of the treatment to ensure patient safety and efficacy of the treatment. Depending on your treatment plan, you will be required to have follow-up visits so your doctor can monitor your progress and adjust your dosages accordingly for optimal outcomes.

Frequently asked questions

The duration of the treatment may vary among individuals, typically a treatment is between 6 – 12 months [5]. Treatment can also be continued until target weight is achieved.
Most patients can see results after 6 months of treatment. Keep in mind that the use of medical weight loss drugs is a supplement, and not a replacement to a balanced diet and regular exercise.

Patients with the following conditions are contraindicated for the use of semaglutide and liraglutide:

  • Thyroid cancer — Thyroid cancer, such as medullary thyroid carcinoma (MTC) - Preclinical trials in mice showed incidences of thyroid cancer with use of semaglutide. Incidences of thyroid cancer in humans are notably low, but caution should be maintained [6].
  •  Multiple endocrine neoplasia syndrome type 2 (MEN2) — GLP-1 receptor agonists are generally contraindicated in patients with personal/familial history of MTC or MEN2 [7].
  • Pancreatitis — Researchers suggest GLP-1 receptor agonists stimulate pancreatic cells, which may cause hyperplasia, increased pancreatic weight, duct occlusion, and inflammation [8].
  • Diabetic retinopathy — Use of semaglutide may increase risk of diabetic retinopathy, especially in patients with retinopathy at baseline.
  • Gallbladder disease — Use of semaglutide was associated with gallbladder and biliary tract disorders such as cholelithiasis and cholecystitis [9].
  • Kidney disease — Use of these medications may increase risk of acute kidney injury.
  • Pregnant or trying to get pregnant — Due to insufficient data on the effects of these medications on pregnancy, caution is advised when in use.
  • Breastfeeding — Insufficient data on the effect of GLP-1 receptor agonist or its metabolites in human milk and potential effects on infants, caution is advised when in use.

Stopping the treatment may cause you to regain some of the weight lost during treatment [10]. However, this can be managed with habit-control, a proper diet and regular exercise.

Summary

Losing weight can be difficult but you don’t have to go through it alone. Your doctor can work with you to understand your needs and goals, guiding you towards safe and effective medical weight loss solutions. Schedule a consultation with us for a comprehensive diagnosis and personalised treatment plan.

References

  1.  https://www.today.com/health/celebrities-on-ozempic-rcna129740
  2. Institute of Medicine (US) Subcommittee on Military Weight Management. Weight Management: State of the Science and Opportunities for Military Programs. Washington (DC): National Academies Press (US); 2004. 4, Weight-Loss and Maintenance Strategies. Available from: https://www.ncbi.nlm.nih.gov/books/NBK221839/
  3. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331.
  4.  Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024 Apr 29;11:1398059. doi: 10.3389/fnut.2024.1398059. PMID: 38742021; PMCID: PMC11090168.
  5.  Guglielmi V, Bettini S, Sbraccia P, Busetto L, Pellegrini M, Yumuk V, Colao AM, El Ghoch M, Muscogiuri G. Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications. Curr Obes Rep. 2023 Jun;12(2):127-146. doi: 10.1007/s13679-023-00502-7. Epub 2023 May 20. PMID: 37209215; PMCID: PMC10250472.
  6.  Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
  7.   Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024 Apr 15;25(8):4346. doi: 10.3390/ijms25084346. PMID: 38673931; PMCID: PMC11050669.
  8. Brunton SA, Mosenzon O, Wright EE Jr. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020 Nov;132(sup2):48-60. doi: 10.1080/00325481.2020.1798162. Epub 2020 Sep 8. PMID: 32815453.
  9. Knapen LM, de Jong RG, Driessen JH, Keulemans YC, van Erp NP, De Bruin ML, Leufkens HG, Croes S, de Vries F. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Diabetes Obes Metab. 2017 Mar;19(3):401-411. doi: 10.1111/dom.12833. Epub 2017 Feb 7. PMID: 27883260.
  10. He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 May 1;182(5):513-519. doi: 10.1001/jamainternmed.2022.0338. PMID: 35344001; PMCID: PMC8961394.
  11. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.

Schedule
an appointment



    contact us
    B2-12 Marina Bay Link Mall, 8A Marina Boulevard, 
Marina Bay Financial Center, Singapore 018984
    Follow us
    Copyright © 2024 Dr Hoe Ying Min
    chevron-down
    WeCreativez WhatsApp Support
    Welcome to Dr Hoe Ying Min!
    👋 Hi, how can I help?